Aquestive Therapeutics Business Summary

Aquestive Therapeutics, Inc. (AQST) operates as a specialty pharmaceutical company utilizing its proprietary PharmFilm® technology to develop and commercialize non-invasive drug delivery systems. The company generates revenue through two primary channels: a Manufacture and Supply segment, which produces licensed products like Suboxone® and Sympazan®, and a proprietary pipeline focused on complex molecule delivery for CNS diseases and severe allergies. As of February 2026, Aquestive is in a critical pre-commercialization phase for Anaphylm™, a sublingual epinephrine film. Following a January 2026 FDA Complete Response Letter (CRL) regarding human factors and packaging, the company is targeting a Q3 2026 resubmission. Aquestive competes directly with ARS Pharmaceuticals (Neffy®), Viatris (EpiPen®), and Jazz Pharmaceuticals, positioning itself as a leader in the needle-free rescue medication market by offering a portable, orally-dissolving alternative to traditional injectors. Aquestive is led by President and CEO Daniel Barber, who joined the firm in 2007 and previously held strategic roles at Quest Diagnostics. The executive team includes Chief Innovation and Technology Officer A. Mark Schobel, a key figure in the development of the PharmFilm platform, and CFO Ernie Toth, who oversees the company's $100M+ cash position. Recent leadership expansions include the appointment of Dr. Matthew Davis as Chief Development Officer in late 2025, bringing over two decades of drug development experience from Neuvivo and Endo Pharmaceuticals, and the return of Dr. Gary Slatko as interim Chief Medical Officer. The company is supported by a robust Board of Directors chaired by Dr. Gregory B. Brown, co-founder of HealthCare Royalty Partners, and Vice Chairman John Cochran, a partner at Crestline Investors. Notable institutional backing includes RTW Investments, reflecting strong investor interest in the company's transition toward a fully integrated commercial entity.